Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Ann Oncol. 2021 May 19;32(8):1050–1051. doi: 10.1016/j.annonc.2021.05.357

Figure 1.

Figure 1.

Kaplan–Meier survival curves without a landmark (1A) and using a 6-month landmark analysis (1B). For the conditional landmark analysis, 2444 patients did not survive until the 6-month landmark and were excluded. Of the 4512 remaining patients, 707 developed thyroiditis within 6 months, whereas 3805 patients either never developed thyroiditis or developed it after the 6-month landmark. Most patients received programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors (87%), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors (5%), and 8% received combined PD-1/CTLA-4.

HR, hazard ratio.